Shalby Ltd
Shalby Ltd is engaged in healthcare delivery space in India. It operates a chain of multi-specialty hospitals across India. The business of the company is to offer tertiary and quaternary healthcare services to patients in various areas of specialization such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, renal transplantations, etc.[1]
The company is the global leader in knee replacement surgery and one of the top Indian hospitals in joint replacement surgery.
- Market Cap ₹ 2,203 Cr.
- Current Price ₹ 204
- High / Low ₹ 325 / 195
- Stock P/E 70.3
- Book Value ₹ 93.2
- Dividend Yield 0.59 %
- ROCE 11.0 %
- ROE 8.16 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 20.0% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 18.1%
Cons
- Company has a low return on equity of 7.39% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
259 | 275 | 290 | 324 | 378 | 462 | 487 | 431 | 699 | 805 | 934 | 1,066 | |
196 | 207 | 235 | 252 | 299 | 379 | 404 | 342 | 577 | 667 | 755 | 916 | |
Operating Profit | 63 | 68 | 56 | 71 | 79 | 83 | 83 | 89 | 122 | 138 | 179 | 151 |
OPM % | 24% | 25% | 19% | 22% | 21% | 18% | 17% | 21% | 17% | 17% | 19% | 14% |
2 | 2 | 2 | 7 | 10 | 9 | 17 | 8 | 8 | 22 | 19 | 27 | |
Interest | 2 | 5 | 10 | 11 | 12 | 9 | 7 | 5 | 8 | 11 | 18 | 35 |
Depreciation | 11 | 21 | 11 | 17 | 23 | 33 | 36 | 37 | 43 | 48 | 52 | 65 |
Profit before tax | 52 | 43 | 36 | 50 | 54 | 50 | 57 | 55 | 79 | 102 | 128 | 78 |
Tax % | 28% | 43% | -1% | 43% | 27% | 37% | 51% | 23% | 32% | 34% | 35% | |
38 | 25 | 36 | 29 | 39 | 32 | 28 | 42 | 54 | 68 | 84 | 30 | |
EPS in Rs | 11.17 | 7.36 | 4.30 | 3.40 | 3.65 | 2.93 | 2.55 | 3.93 | 5.01 | 6.27 | 7.78 | 3.13 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 17% | 20% | 25% | 20% | 19% | 15% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 15% |
3 Years: | 29% |
TTM: | 20% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 20% |
3 Years: | 22% |
TTM: | -61% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 17% |
1 Year: | -31% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 6% |
3 Years: | 7% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 35 | 35 | 87 | 87 | 108 | 108 | 108 | 108 | 108 | 107 | 107 | 107 |
Reserves | 106 | 133 | 117 | 164 | 643 | 672 | 691 | 727 | 768 | 820 | 893 | 899 |
37 | 98 | 224 | 328 | 114 | 71 | 62 | 44 | 155 | 180 | 378 | 463 | |
39 | 85 | 75 | 99 | 96 | 89 | 105 | 118 | 162 | 173 | 231 | 247 | |
Total Liabilities | 217 | 351 | 504 | 679 | 961 | 939 | 967 | 997 | 1,194 | 1,281 | 1,609 | 1,717 |
130 | 175 | 319 | 323 | 650 | 692 | 672 | 660 | 675 | 685 | 966 | 971 | |
CWIP | 5 | 91 | 82 | 221 | 47 | 3 | 6 | 8 | 6 | 11 | 15 | 11 |
Investments | 0 | 0 | 0 | 0 | 0 | 11 | 28 | 16 | 25 | 146 | 81 | 112 |
81 | 85 | 102 | 134 | 264 | 233 | 260 | 314 | 488 | 440 | 547 | 623 | |
Total Assets | 217 | 351 | 504 | 679 | 961 | 939 | 967 | 997 | 1,194 | 1,281 | 1,609 | 1,717 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
60 | 14 | 43 | 55 | 79 | 19 | 68 | 20 | ||||
-153 | -236 | 1 | -31 | -51 | -60 | -61 | 146 | ||||
96 | 222 | -51 | -22 | -30 | 90 | -50 | -151 | ||||
Net Cash Flow | 3 | 0 | -6 | 3 | -2 | 49 | -43 | 15 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 21 | 29 | 40 | 38 | 49 | 64 | 71 | 80 | 53 | 48 | 57 |
Inventory Days | 77 | 113 | 119 | 105 | 242 | 1,152 | 1,361 | ||||
Days Payable | 395 | 462 | 522 | 415 | 606 | 546 | 744 | ||||
Cash Conversion Cycle | 21 | 29 | 40 | -280 | -299 | -339 | -239 | -283 | 53 | 654 | 673 |
Working Capital Days | 35 | -46 | -26 | -34 | -3 | 57 | 70 | 84 | 109 | 111 | 107 |
ROCE % | 22% | 13% | 12% | 9% | 7% | 7% | 7% | 10% | 10% | 11% |
Documents
Announcements
-
Receipt Of Hand Transplant Approval
11 Feb - Shalby Hospital receives approval for hand transplants.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Feb - Newspaper Advertisement relating to dispatch of Postal Ballot Notice and Remote e-voting information
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
11 Feb - Transcript of Q3 FY25 Earnings Conference Call released.
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 10 Feb
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
7 Feb - Grant of ESOP under Shalby Limited Stock Option Scheme-2021
Annual reports
Concalls
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Jul 2023Transcript PPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Dec 2021Transcript PPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
May 2021Transcript PPT
-
May 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Jan 2021Transcript PPT
-
Jan 2021TranscriptNotesPPT
-
Oct 2020TranscriptPPT
-
Oct 2020Transcript PPT
-
Sep 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Jul 2019Transcript PPT
-
May 2019Transcript PPT
-
Jan 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
Mar 2018TranscriptNotesPPT
Business Segments
1) Healthcare Services (90% in H1 FY25 vs 96% in FY22): [1] [2] The company manages a network of 11 multispecialty tertiary hospitals and 5 orthopedic centers spanning 13 cities across India, with a total capacity of over 2,350 hospital beds, it provides services across 30+ specialties. Additionally, it operates 60 outpatient clinics domestically and 23 internationally. Between FY22 and FY24, segment revenue increased by 28%, driven by growth in in-patient numbers, including daycare services, and overall surgery count. [3] [4]